<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - SIROLIMUS</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>SIROLIMUS</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of organ rejection in kidney allograft recipients</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 6 mg for 1 dose, to be given after surgery once wound has healed, then 2 mg once daily for 2&#8211;3 months (in combination with ciclosporin and corticosteroid; sirolimus dose should be given 4 hours after ciclosporin), followed by maintenance 2 mg once daily, ciclosporin should then be withdrawn over 4&#8211;8 weeks (if not possible, sirolimus should be discontinued and an alternate immunosuppressive regimen used), dose to be adjusted according to whole blood-sirolimus trough concentration.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>The 500&#8239;microgram tablet is not bioequivalent to the 1&#8239;mg and 2&#8239;mg tablets. Multiples of 500&#8239;microgram tablets should <b>not</b> be used as a substitute for other tablet strengths.</p>
            </section>
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>
            <b>Sirolimus</b> is a non-calcineurin inhibiting immunosuppressant.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Avoid unless essential&#8212;toxicity in <i>animal</i> studies.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>In severe impairment decrease dose by 50% and monitor whole blood-sirolimus trough concentration every 5&#8211;7 days until 3 consecutive measurements have shown stable blood-sirolimus concentration.</p>
            </section>
            <section class="generalInformation">
              <p>Clearance reduced in mild to moderate impairment.</p>
            </section>
      </section>



      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Abdominal pain, acne, anaemia, arthralgia, ascites, constipation, diarrhoea, epistaxis, haemolytic uraemic syndrome, headache, hypercholesterolaemia, hyperglycaemia, hypertension, hypertriglyceridaemia, hypokalaemia, hypophosphataemia, impaired healing, leucopenia, lymphocele, nausea, neutropenia, oedema, osteonecrosis, pleural effusion, pneumonitis, proteinuria, pyrexia, rash, stomatitis, tachycardia, thrombocytopenia, thrombotic thrombocytopenic purpura, venous thromboembolism,
              </p>
              <p>
                <strong>uncommon:</strong> Nephrotic syndrome, pancreatitis, pancytopenia, pericardial effusion, pulmonary embolism, pulmonary haemorrhage,
              </p>
              <p>
                <strong>rare:</strong> Alveolar proteinosis, anaphylactic reactions, angioedema, exfoliative dermatitis, hepatic necrosis, hypersensitivity reactions, hypersensitivity vasculitis, interstitial lung disease, lymphoedema,
              </p>
              <p>
                <strong>notKnown:</strong> Focal segmental glomerulosclerosis, reversible impairment of male fertility,
              </p>
        
        
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <p>Food may affect absorption (take at the same time with respect to food). Sirolimus oral solution should be mixed with at least 60&#8239;mL water or orange juice in a glass or plastic container immediately before taking; refill container with at least 120&#8239;mL of water or orange juice and drink immediately (to ensure total dose). Do not mix with any other liquids.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Patient or carers should be given advice on how to administer sirolimus.</p>
            </section>
            <section class="generalPatientAdvice">
              <p>Patients should be advised to avoid excessive exposure to UV light.</p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Hyperlipidaemia
          </li>
          <li>
            increased susceptibility to infection (especially urinary-tract infection)
          </li>
          <li>
            increased susceptibility to lymphoma and other malignancies, particularly of the skin (limit exposure to UV light)
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <p>Effective contraception must be used during treatment and for 12 weeks after stopping.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <p>Monitor whole blood-sirolimus trough concentration (Afro-Caribbean patients may require higher doses).</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <p>Manufacturer advises pre-dose (&#8216;trough&#8217;) whole blood-sirolimus concentration (using <b>chromatographic</b> assay) when used with ciclosporin should be 4&#8211;12&#8239;micrograms/litre (local treatment protocols may differ); after withdrawal of ciclosporin pre-dose whole blood-sirolimus concentration should be 12&#8211;20&#8239;micrograms/litre (local treatment protocols may differ).</p><p>Close monitoring of whole blood-sirolimus concentration required if concomitant treatment with potent inducers or inhibitors of metabolism and after discontinuing them, or if ciclosporin dose reduced significantly or stopped.</p><p>When changing between oral solution and tablets, measurement of whole blood &#8216;trough&#8217; sirolimus concentration after 1&#8211;2 weeks is recommended.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
                <h3>Therapeutic drug monitoring assays</h3>
              <p>Sirolimus whole-blood concentration is measured using either high performance liquid chromatography (HPLC) or immunoassay. Switching between different immunoassays or between an immunoassay and HPLC can lead to clinically significant differences in results and therefore incorrect dose adjustments. Adjustment to the target therapeutic dose range should be made with knowledge of the assay used and corresponding reference range.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <p>Monitor kidney function when given with ciclosporin; monitor lipids; monitor urine proteins.</p>
            </section>
      </section>











      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of SIROLIMUS</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75367"><a href="../medicinalForm/PHP75367.html" data-target="#PHP75367" data-action="load">Tablet</a></div>
            <div id="PHP75361"><a href="../medicinalForm/PHP75361.html" data-target="#PHP75361" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
